Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Blocklisting Interim Review

14 Aug 2015 13:57

RNS Number : 1309W
ABCAM Plc
14 August 2015
 



For immediate release

14 August 2015

ABCAM PLC

("Abcam" or "the Company")

 

Block Admission Return

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:

Abcam plc

Name of scheme:

1. Abcam EMI Scheme

2. Abcam SAYE Scheme

3. Abcam 2005 Share Option Scheme

4. Abcam Share Incentive Plan

5. Abcam Company Share Option Plan

6. Abcam Long Term Incentive Plan

7. Annual Bonus Plan

Period of return:

From:

6 February 2015

To:

7 August 2015

Balance of unallotted securities under scheme(s) from previous return:

1. 560,915

2. 31,405

3. 2,660,309

4. 281,146

5. 683,238

6. 1,965,749

7. 399,479

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1. -

2. -

3. -

4. -

5. -

6. -

7. -

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

1. -

2. -

3. 133,504

4. -

5. 53,056

6. -

7. -

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1. 560,915

2. 31,405

3. 2,526,805

4. 281,146

5. 630,182

6. 1,965,749

7. 399,479

 

Name of contact:

Laura Taylor, Investor Relations

Telephone number of contact:

01223 696000

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

Laura Taylor, Investor Relations Manager

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Alex Bruce - Nominated Adviser

Peel Hunt LLP - Joint Corporate Broker

+ 44 (0) 20 7418 8900

Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking

 

FTI Consulting

+44 (0) 20 3727 1000

Ben Atwell / Brett Pollard / Natalie Garland-Collins

 

Notes to Editors

 

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRBDGDILUBBGUS
Date   Source Headline
7th Mar 20132:59 pmRNSDirector/PDMR Shareholding
7th Mar 20132:48 pmRNSHolding(s) in Company
6th Mar 20136:16 pmRNSDirector/PDMR Shareholding
5th Mar 20137:00 amRNSInterim Results
5th Mar 20137:00 amRNSHolding(s) in Company
26th Feb 20134:17 pmRNSDirector/PDMR Shareholding
20th Feb 20134:42 pmRNSHolding(s) in Company
12th Feb 20137:00 amRNSNotification of Interim Results
29th Jan 20136:18 pmRNSDirector/PDMR Shareholding
28th Jan 20135:15 pmRNSHolding(s) in Company
22nd Jan 20137:00 amRNSHalf Year Trading Update
15th Jan 20136:12 pmRNSHolding(s) in Company
31st Dec 20127:00 amRNSDirector/PDMR Shareholding
3rd Dec 20125:50 pmRNSTotal Voting Rights
30th Nov 20121:10 pmRNSDirector/PDMR Shareholding
9th Nov 201211:58 amRNSDirector/PDMR Shareholding
5th Nov 20123:14 pmRNSDirector/PDMR Shareholding
2nd Nov 20121:03 pmRNSDirector/PDMR Shareholding
1st Nov 20124:56 pmRNSTotal Voting Rights
29th Oct 201212:01 pmRNSDirector/PDMR Shareholding
22nd Oct 20121:52 pmRNSAGM Statement
22nd Oct 20127:00 amRNSAGM Statement
18th Oct 201212:19 pmRNSHolding(s) in Company
10th Oct 20123:59 pmRNSDirector/PDMR Shareholding
8th Oct 20129:32 amRNSDirector/PDMR Shareholding
4th Oct 20124:14 pmRNSDirector/PDMR Shareholding
2nd Oct 20129:16 amRNSHolding(s) in Company
1st Oct 201212:12 pmRNSHolding(s) in Company
1st Oct 201212:03 pmRNSTotal Voting Rights
28th Sep 201212:19 pmRNSDirector/PDMR Shareholding
28th Sep 201211:45 amRNSHolding(s) in Company
21st Sep 20124:26 pmRNSAnnual Report & Accounts
12th Sep 20126:06 pmRNSHolding(s) in Company
6th Sep 20127:00 amRNSPreliminary Results 2012
30th Aug 20127:00 amRNSNotification of Preliminary Results
28th Aug 20127:00 amRNSPDMR Shareholding
30th Jul 20127:00 amRNSPDMR Shareholding
25th Jul 20127:00 amRNSFull Year Trading Update
2nd Jul 20127:00 amRNSPDMR Shareholding
21st Jun 20124:06 pmRNSHolding(s) in Company
28th May 201211:25 amRNSPDMR Shareholding
16th May 201210:53 amRNSHolding(s) in Company
8th May 201212:36 pmRNSPDMR Shareholding
1st May 20125:15 pmRNSTotal Voting Rights
27th Apr 20125:18 pmRNSPDMR Shareholding
23rd Apr 20125:37 pmRNSDirector Shareholding
20th Apr 20127:00 amRNSCompletion of Tender Offer
2nd Apr 20127:00 amRNSPDMR Shareholding
2nd Apr 20127:00 amRNSTotal Voting Rights
28th Mar 201212:34 pmRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.